Prof. Peter Stalmans is an internationally recognized vitreoretinal surgeon and clinical researcher with more than 25 years of leadership in vitreoretinal disease, surgical innovation, and pharmacologic vitreolysis. He is Head of Clinic at the Department of Ophthalmology, University Hospitals Leuven (UZ Leuven), and Associate Professor at KU Leuven, one of Europe’s leading academic medical centers. Prof. Stalmans is widely regarded for his pioneering work on the vitreomacular interface, especially as a principal investigator and senior author in the ocriplasmin (microplasmin).
KEY INTERESTS AND RESEARCH HIGHLIGHTS
- Principal investigator or co‑investigator in multiple phase I–III trials involving pharmacologic vitreolysis, surgical platforms, and vitreoretinal devices.
- Lead and senior author for the MIVI‑TRUST trials and related studies that established enzymatic vitreolysis as a therapeutic approach (NEJM, Ophthalmology, Retina).
- Extensive experience moving therapies from first‑in‑human studies through pivotal trials and post‑market evaluation.
- Author or co‑author of 200+ peer‑reviewed publications, editorials, and book chapters in leading journals.
